Clover (三叶草生物) Pre-IPO: COVID-19 Wildcard

320 Views17 Oct 2021 10:31
We look at Clover's key products, including SCB-2019 (COVID-19 vaccine), SCB-313 (for intracavitary malignancies), and SCB-808 (biosimilar of Enbrel with novel formulation).
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Ke Yan, CFA, FRM
Asia Pac IPO & Placement Research, China biotech
Aequitas Research
EquitiesEquity Capital MarketsQuantitative Analysis
Price Chart(Sign Up to Access)
analytics-chart
x